RTP Mobile Logo

A randomized, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with gBRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. NCT02032823

Albain KS et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11(1):55-65. Abstract

Barroso-Sousa R et al. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care (Basel) 2016;11(3):167-73. Abstract

Bartlett JM et al; OPTIMA TMG. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: No test is more equal than the others. J Natl Cancer Inst 2016;108(9). Abstract

Finn RS et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925-36. Abstract

Finn RS et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015;16(1):25-35. Abstract

Goetz MP et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35(32):3638-46. Abstract

Goss PE et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 — A randomized controlled phase III trial. J Clin Oncol 2013;31(11):1398-404. Abstract

Hortobagyi GN et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375(18):1738-48. Abstract

Jimenez MM et al. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5 year analysis of the phase III ExteNET trial. Proc ESMO 2017;Abstract 149O.

Leung SCY et al. Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration. NPJ Breast Cancer 2016;2:16014. Abstract

Masuda N et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017;376(22):2147-59. Abstract

Pagani O et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. San Antonio Breast Cancer Symposium 2017;Abstract GS4-02.

Rimawi MF et al. A phase III trial evaluating pCR rates with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation: NRG Oncology/NSABP B-52. San Antonio Breast Cancer Symposium 2016;Abstract S3-06.

Robertson JFR et al. Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer — The POETIC trial (CRUK/07/015). San Antonio Breast Cancer Symposium 2017;Abstract GS1-03.

Sestak I et al. Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 2015;33(8):916-22. Abstract

Sledge GW et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35(25):2875-84. Abstract

Sparano JA et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015;373(21):2005-14. Abstract

Straver ME et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010;119(3):551-8. Abstract

Swain SM et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372(8):724-34. Abstract

Von Minckwitz G et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377(2):122-31. Abstract